The European Commission (EC) has granted a marketing authorisation for Opzelura (ruxolitinib) cream 15 mg/g for the treatment of nonsegmental vitiligo with facial involvement in adults and adolescents from 12 years of age.
The approval is based on the results of two pivotal phase 3 trials ( TRuE-V1 and TRuE-V2 ...